Role of vasopressin antagonists in the management of acute decompensated heart failure.

被引：6

作者：

Orlandi C. ^{[1
]}

Zimmer C.A. ^{[1
]}

Gheorghiade M. ^{[1
]}

机构：

[1] Department of Clinical Development, Otsuka Maryland Research Institute, Inc., 2440 Research Boulevard, Rockville, 20850, MD

来源：

Current Heart Failure Reports | 2005年 / 2卷 / 3期

关键词：

Vasopressin; Chronic Heart Failure; Serum Sodium; Pulmonary Capillary Wedge Pressure; Tolvaptan;

D O I：

10.1007/s11897-005-0021-3

中图分类号：

学科分类号：

摘要：

Vasopressin antagonists are a class of neurohormonal antagonists with applications in both the short-term and long-term management of patients with acute decompensated heart failure (ADHF). The pharmacologic effects of vasopressin antagonists include changes in fluid balance and hemodynamics that may improve symptoms and outcomes in patients hospitalized with ADHF. With chronic therapy, vasopressin antagonists offer the potential to improve outcomes through a variety of mechanisms, including more effective treatment of congestion, preservation or improvement of renal function, or a reduction in the use of concomitant loop diuretic therapy. Several vasopressin antagonists are currently in advanced clinical trials for the treatment of ADHF, chronic stable heart failure, and hyponatremia.

引用

页码：131 / 139

页数：8